New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2013
04:55 EDTAMGN, AMGN, INCY, INCY, JNJ, JNJ, NPSP, NPSP, SRPT, SRPT, PRXL, PRXL, HSP, HSP, PFE, PFE, GSK, GSK, ALKS, ALKS, BMY, BMYElsevier Business Intelligence to hold a summit
FDA / CMS Summit: 2014 Crossroads or Turning Point is being held in Washington, D.C. on December 11-12.
News For AMGN;ALKS;GSK;PFE;HSP;PRXL;SRPT;NPSP;JNJ;INCY;BMY From The Last 14 Days
Check below for free stories on AMGN;ALKS;GSK;PFE;HSP;PRXL;SRPT;NPSP;JNJ;INCY;BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 6, 2014
13:46 EDTPFEPfizer's palbociclib significantly prolonged PFS in metastatic breast cancer
Subscribe for More Information
April 4, 2014
09:02 EDTAMGNAmgen announces analysis results of Phase 3 trial of talimogene laherparepvec
Subscribe for More Information
06:29 EDTGSKGlaxoSmithKline cuts China employees amid probe, WSJ reports
According to a source, as it deals with a bribery probe in Beijing, GlaxoSmithKline is cutting employees in China, the Wall Street Journal reports. It is unclear how many of Glaxo's 7,000 employees in China have been let go. Reference Link
April 3, 2014
12:32 EDTSRPTExpert thinks FDA could be swayed on eteplirsen by families, Boston Herald says
Subscribe for More Information
09:37 EDTGSK, AMGNAmgen to pay GlaxoSmithKline $275M to terminate denosumab collaboration pact
Subscribe for More Information
09:30 EDTPFEApple, Pfizer others create 'go slow' patent lobby group, Reuters says
Subscribe for More Information
08:27 EDTAMGN, PFELeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
05:50 EDTPFEStocks with implied volatility movement; OXY PFE
Subscribe for More Information
April 2, 2014
11:55 EDTPFEUniqure rises after Baxter acquires Chatham Therapeutics
Subscribe for More Information
10:00 EDTALKSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:18 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTALKSCelgene to buy 1.1M shares of Acceleron Pharma for $47.15M
Subscribe for More Information
08:40 EDTJNJPiper Jaffray to hold booth tours
Booth Tours at SAGES Annual Meeting will be held in Salt Lake City, Utah on April 2-3.
08:31 EDTNPSPSociety of American Gastrointestinal & Endoscopic Surgeons holds annual meeting
2014 Annual Meeting of SAGES is being held in Salt Lake City, Utah on April 2-5.
07:44 EDTGSKAgenus down 9.4% after GlaxoSmithKline stops MAGRITi Phase 3 trial
Subscribe for More Information
06:46 EDTALKSAlkermes initiated with an Outperform at Credit Suisse
Target $57.
06:25 EDTHSPThe Medicines Co. downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded The Medicines Co. (MDCO) to Neutral after a court ruled the company failed to prove its patents were infringed by Hospira (HSP).
06:11 EDTGSKGlaxoSmithKline confirms plans to stop MAGRIT Phase III trial
GlaxoSmithKline announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment. Data from the trial announced on 20 March 2014 showed that it did not meet its first or second co-primary endpoints as it did not significantly extend disease-free survival when compared to placebo in either the overall MAGE-A3 positive population or in those MAGE-A3-positive patients who did not receive chemotherapy. The trial will be stopped and GSK will now gain access to the un-blinded data, in order to conduct a full assessment of the findings and understand learnings for other aspects of immunotherapy development within GSK. The Independent Data Monitoring Committee indicated that its review of the current safety information revealed no specific safety concern and the data is in line with the known safety information for the MAGE-A3 cancer immunotherapeutic.
06:05 EDTALKSAlkermes initiated with an Outperform at Credit Suisse
Subscribe for More Information
05:45 EDTGSKAgenus announces GSK's MAGE-A3 Phase 3 study will be stopped
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use